Zolgensma R&D subsidies
Author: James Love
KEI Statement on Adoption of the WHA72 Transparency Resolution
Today the World Health Assembly (WHA) approved A72/A/CONF./2 Rev.1 as a resolution, titled “Improving the transparency of markets for medicines, vaccines, and other health products.” Link to the resolution: http://apps.who.int/gb/ebwha/pdf_files/WHA72/A72_ACONF2Rev1-en.pdf When the text was made available, I sent out a… Continue Reading
The growing gap between what the public had been told R&D costs are, and the actual costs
One of the reasons why drug companies have fought so hard to block transparency of clinical trial costs is the growing gap between what the public had been told those costs are, and the actual costs, particularly for treatments for… Continue Reading
Comments on the transparency resolution negotiation process
An earler version of this was posted to ip-health. —– As the #TransparencyResolution finally moves onto the #WHA72 agenda, I would like to offer a few comments on the process. We have copies of six versions of the negotiating text,… Continue Reading
WHO publishes May 22 version of transparency resolution with 110 brackets. We compare to original proposal.
The WHO has published A72/A/CONF./2, for Agenda item 11.7. The date of the document is 23 May 2019, but it is the end of day negotiating text from Wed, May 22. The title is: Improving the transparency of markets for… Continue Reading
How transparency of the costs of clinical trials will improve policy making
Perhaps the toughest issue in the 72nd World Health Assembly negotiations on a WHO transparency resolution concerns the proposal to require public reporting of the costs of each clinical trial undertaken for development of drugs, vaccines, cell- and gene-therapies and… Continue Reading
Italy and 11 co-sponsors introduce transparency resolution text to WHA72
Politico has published a copy of the new draft of the World Health Assembly (WHA) transparency resolution. WHA-Resolution_DRAFT_20-05-2019 The Politico account cites the disclosure of clinical trial costs as one area for transparency that is strongly opposed by some governments,… Continue Reading
Comparison between April 29 and May 7 version of WHA 72 resolution on transparency
At the May 7 informal, countries from Northern Europe with strong pharma industry lobbies proposed dozens of changes in the transparency resolution to make it weaker and in many cases confusing and meaningless. This table compares the two texts: Dif-April29-May7-WHA-Transparency-Resolution… Continue Reading
KEI comments at HHS listening session on WHA72 concerning the transparency resolution
On Agenda item 11.7 – Access to medicines and vaccines, KEI offers the following comments on the transparency resolution. 1. Transparency should not be controversial. Policy makers and the public need to have better evidence in order to support policies… Continue Reading
State of Georgia, et al., v Public.Resource.Org, Inc., Amici Curiae in Support of Respondent’s Acquiescence in the Petition
KEI was one of 13 groups to support Public.Resource.Org in this important litigation over the ability of state governments to “leverage copyright to raise access barriers to important sources of legal information.” Charles Duan for the R-Street Institute is the… Continue Reading